Login to Your Account



ASCO 2011 Roundup

Exelixis Shares Dive on 'Cabo' Safety Data; Prostate Shines

By Staff Reports


Tuesday, June 7, 2011
Investors may be looking to Exelixis Inc. for comfort during the biotech's Monday evening conference call, particularly after a series of analyses from a Phase II trial of cabozantinib (XL184) presented over the weekend at the American Society of Clinical Oncology's (ASCO) 2011 annual meeting sent shares tumbling 20.2 percent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription